Scarica l'app Stockscreener
2.31
7.44%
0.16
Pre-mercato:
2.18
-0.13
-5.63%
Xortx Therapeutics Inc Borsa (XRTX) Ultime notizie
XORTX Therapeutics stock gains as Nasdaq listing takes center stage - AD HOC NEWS
XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History - Yahoo Finance
XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign - TipRanks
$2.5M, three months, 10 campaigns: XORTX (Nasdaq: XRTX) bets big on investor marketing after TSXV delist - Stock Titan
XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 ResistanceOverbought Signal Alerts - siam.in
XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum - kalkine.ca
XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign - Stock Titan
XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting - TipRanks
XORTX Gets US$2.5M Back as TSX Venture Exchange Delisting Awaits Approval - Stock Titan
XORTX Announces Termination and Postponement of Investor Relations Program - GlobeNewswire
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - valueresearchonline.com
XORTX Therapeutics (TSXV:XRTX) Shares Jump 10.8% in a Volatile Session - kalkine.ca
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet - TipRanks
Going-concern warning at XORTX (XRTX) as losses mount - Stock Titan
XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
XORTX Therapeutics (XRTX) Advances 5.28% as Shares Test Resistance at $2.38Institutional Sentiment - vinanet.vn
XORTX (XRTX) Q1 2024 Earnings: Loss of -$1.24 per Share Misses Consensus by 372.2%Earnings Revision Upgrade - vinanet.vn
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo - The Globe and Mail
XORTX Therapeutics (XRTX) Edges Higher at $2.21 as Shares Hold Mid-Range PositionLong Term Entry Picks - dars.gov.et
Board chair exit at XORTX Therapeutics (NASDAQ: XRTX) detailed - Stock Titan
XORTX Therapeutics (XRTX) Climbs 4.92% as Shares Approach Key Resistance at $2.23Fundamentals - dars.gov.et
XORTX Therapeutics (XRTX) Climbs 4.92% to $2.12 as Speculative Interest BuildsSwing Entry Signals - dars.gov.et
XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role - marketscreener.com
XORTX Director Anthony Giovinazzo Steps Down for Personal Reasons - Stock Titan
XRTX Q1 2024 Earnings: Larger-Than-Expected Loss Highlights Developmental Stage ChallengesProfitability Analysis - vinanet.vn
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight - TipRanks
XORTX Therapeutics (NASDAQ: XRTX) appoints Depesh Narotam as independent director - Stock Titan
XORTX Appoints New Director - GlobeNewswire
XORTX Therapeutics, Inc. Revenue Breakdown – TSXV:XRTX - TradingView
Vectus Biosystems Appoints Dr Tara Speranza as CEO and CTO, Raises $791,000 to Accelerate VB0004 Clinical Development - Kalkine
Why XORTX Therapeutics Inc stock is sliding today - Wealth Awesome
XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XRTX|XORTX Therapeutics Inc|Price:2.025|Chg%:-0.090 - TradingKey
XRTX|XORTX Therapeutics Inc|Price:2.015|Chg%:-0.010 - TradingKey
XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
XORTX Therapeutics Inc (XRTX) Institutional Confidence - TradingKey
XORTX Therapeutics Inc (XRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XORTX Therapeutics Inc (XRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XORTX Therapeutics Inc. Revenue Breakdown – NASDAQ:XRTX - TradingView
XORTX Therapeutics Inc (XRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XORTX Therapeutics, Inc. Revenue Breakdown – NEO:XRTX - TradingView
XORTX Therapeutics(XRTX) Stock Options Chain | Quotes & News - Moomoo
XORTX Therapeutics (XRTX) Investor presentation Summary - Quartr
XORTX Therapeutics (XRTX) Q4 2024 earnings summary - Quartr
Price to earnings forward of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView
XORTX Therapeutics (XRTX) Rallies 3.3% as Biotech Sector Gains MomentumMoney Flow - dars.gov.et
XORTX Therapeutics (XRTX) Gains 3.33% as Biotech Momentum BuildsDescending Triangle - dars.gov.et
XRTX Q1 2024 Earnings: Pre‑Revenue Biotech Reports EPS Miss as Clinical Pipeline AdvancesDiluted EPS Report - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Xortx Therapeutics updates investors on kidney disease focus - ad-hoc-news.de
XORTX Therapeutics Company Profile & Introduction - Moomoo
XRTX Q1 2024 Earnings: Significant EPS Miss Reflects Preclinical Stage ChallengesQuarterly Earnings - dars.gov.et
Enterprise value to EBIT forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Price to sales forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Enterprise value to revenue forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Why XORTX Therapeutics Inc stock is skyrocketing today - Wealth Awesome
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
XRTX Q1 2024 Earnings: Significant EPS Miss Highlights Challenges in Clinical-Stage BiotechEarnings Growth Analysis - dars.gov.et
XRTX Q1 2024 Earnings: Significant EPS Miss Amid Operational DevelopmentsEarnings Surprise Stocks - DonanımHaber
XORTX Therapeutics (XRTX) Edges Higher as Stock Remains Within Defined RangeVolume Gap - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Slides 2.79% as Shares Test Key Support Near $2.00Stock Surge Alerts - dars.gov.et
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):